Literature DB >> 18341429

Aggregation and amyloid fibril formation of the prion protein is accelerated in the presence of glycogen.

Giannantonio Panza1, Jan Stöhr, Eva Birkmann, Detlev Riesner, Dieter Willbold, Otto Baba, Tatsuo Terashima, Christian Dumpitak.   

Abstract

Prion diseases like Creutzfeldt-Jakob disease in humans or scrapie in sheep and goats are infectious neurodegenerative diseases. Their infectious agent, called prion, is composed mainly of aggregated and misfolded prion protein and non-proteinaceous components. An example of such a common non-proteinaceous secondary component of natural prions is the polysaccharide scaffold. We studied the influence of such a polysaccharide on the conformational transition of PrP applying an in vitro conversion system. Here we report that glycogen supports and accelerates PrP amorphous aggregation similar to seeded aggregation and leads to co-aggregates. Furthermore, PrP fibril formation was highly accelerated in the presence of glycogen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18341429     DOI: 10.1089/rej.2008.0698

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  3 in total

Review 1.  Structural requirements for efficient prion protein conversion: cofactors may promote a conversion-competent structure for PrP(C).

Authors:  Andrew C Gill; Sonya Agarwal; Teresa J T Pinheiro; James F Graham
Journal:  Prion       Date:  2010-10-20       Impact factor: 3.931

Review 2.  Self-assembling peptide and protein amyloids: from structure to tailored function in nanotechnology.

Authors:  Gang Wei; Zhiqiang Su; Nicholas P Reynolds; Paolo Arosio; Ian W Hamley; Ehud Gazit; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2017-07-31       Impact factor: 54.564

3.  Recombinant prion protein refolded with lipid and RNA has the biochemical hallmarks of a prion but lacks in vivo infectivity.

Authors:  Andrew G Timmes; Roger A Moore; Elizabeth R Fischer; Suzette A Priola
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.